Calliditas Therapeutics AB ADR (CALT) Social Stream

Featured Post From StockTwits About CALT

$CALT announced that the FDA has granted Fast Track Designation for its lead NOX inhibitor candidate setanaxib for the treatment of patients with the chronic orphan liver disease primary biliary cholangitis https://www.briefing.com/in-depth-analysis/Content/Article?ArticleId=IN20210809045017CALT